<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857817</url>
  </required_header>
  <id_info>
    <org_study_id>VT1-SYS-601</org_study_id>
    <nct_id>NCT01857817</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer</brief_title>
  <official_title>A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vicus Therapeutics</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical benefit of the co-administration of
      propranolol and etodolac (VT-122 therapy) in patients with clinically progressive prostate
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low patient recruitment
  </why_stopped>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in prostate specific antigen (PSA)</measure>
    <time_frame>baseline (Day 1 Cycle 1) to 12 weeks (Day 1, Cycle 4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA progression</measure>
    <time_frame>baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA doubling time (PSADT)</measure>
    <time_frame>baseline and every month during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported performance (EQ-5D), pain (visual analog scale [VAS] and opiate usage)</measure>
    <time_frame>Day 1 Cycle 1, on Day 1 of each subsequent 28-day cycle, and on end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to symptom progression (TTSP)</measure>
    <time_frame>Day 1 Cycle 1 and Day 1 of each subsequent 28-day cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in correlative biomarkers</measure>
    <time_frame>Day 1 Cycle 1, on Day 1 of each subsequent 28-day cycle, and on end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>VT-122 with physician's choice therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with physician's choice therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VT-122</intervention_name>
    <description>The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.</description>
    <arm_group_label>VT-122 with physician's choice therapy</arm_group_label>
    <other_name>propranolol</other_name>
    <other_name>etodolac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo capsules will be prepared to match the active drug.</description>
    <arm_group_label>Placebo with physician's choice therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a confirmed diagnosis of prostate cancer

          2. Male participants who are ≥18 years of age

          3. In the opinion of the investigator, the participants have a life expectancy of at
             least 3 months.

          4. Two consecutively rising PSA values or two out of three rising PSA values (2.0 ng/mL
             is the minimum ending value for PSA) at a minimum of 1-week intervals

          5. Have a Karnofsky Performance Score (KPS) equal to or greater than 70

          6. Have the following laboratory parameters (may be assessed locally):

               1. Platelet count ≥50 x 10E3/µL

               2. Total bilirubin ≤1.5 mg/dL

               3. Serum creatinine ≤1.5 x upper limit of normal (ULN) or creatinine clearance &gt;60
                  mL/min calculated using Cockcroft-Gault

               4. Liver enzymes [aspartate transaminase (AST), alanine transaminase (ALT)] ≤2 x ULN

          7. Able to provide written informed consent prior to any study specific screening
             procedures with the understanding that the patient has the right to withdraw from the
             study at any time, for any reason without prejudice

        Exclusion Criteria:

          1. The patient has a history of another primary cancer, with the exception of:

               1. Curatively resected non-melanomatous skin cancer;

               2. Other primary solid tumor with no known active disease presents that in the
                  opinion of the investigator that will not affect patient outcome in the setting
                  of current prostate cancer diagnosis.

          2. Contraindication to propranolol, etodolac

          3. Patients on beta blockers

          4. Patients receiving chemotherapy (e.g., docetaxel, cabazitaxel, taxane, or platinum as
             single agents or in combination) as their cancer treatment

          5. History or evidence of cardiac disease: congestive heart failure; New York Heart
             Association class 2 or greater; active coronary artery disease; unstable angina,
             cardiac arrhythmias requiring anti-arrhythmic therapy, atrio-ventricular block of
             second or third degree, or uncontrolled hypertension, patients with recent (less than
             6 months) myocardial infarction (MI) or coronary revascularization

          6. Hypotension at the time of screening (i.e., systolic blood pressure less than 110
             mmHg. Diastolic blood pressure less than 60 mmHg)

          7. Resting heart rate less than 60 bpm at time of screening

          8. Any uncontrolled, intercurrent illness that in the opinion of the Investigator may
             interfere with study evaluation. Participants with uncontrolled diabetes will be
             excluded from the study.

          9. On chronotropic drugs (acetylcholine, digoxin, diltiazem, verapamil, atropine,
             dopamine, dobutamine, epinephrine, isoproterenol)

         10. Active clinically serious infections [&gt; Grade 2 National Cancer Institute (NCI)-Common
             Terminology Criteria for Adverse Events (CTCAE) version 4.0]

         11. Substance abuse, medical, psychological or social conditions that may, in the opinion
             of the investigator, interfere with the patient's participation in the study or
             evaluation of the study results

         12. Known or suspected allergy to the investigational agents or any agent given in
             association with this trial (hypersensitivity reaction, hives, rash, difficulty
             breathing swelling of your face, lips, tongue, or throat)

         13. Any condition that is unstable or which in the opinion of the Investigator could
             jeopardize the safety of the patient and his/her compliance in the study

         14. Patients with uncontrolled diabetes or insulin resistance

         15. Participation in any other investigational trial in which receipt of investigational
             drug or device occurred within 30 days prior to screening for this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redwood Regional Medical Group</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Urology</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manatee Medical Research Institute, LLC</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwestern Regional Medical Center</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center, PC</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult &amp; Pediatric Urology</name>
      <address>
        <city>Sartell</city>
        <state>Minnesota</state>
        <zip>56377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hendrick Cancer Center</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Etodolac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

